J&J purchases Crucell shares, inks influenza drug deal

09/28/2009 | Wall Street Journal, The

Johnson & Johnson will pay $442.7 million to get an 18% stake in Crucell and collaborate with the Dutch biotech firm on the development and marketing of a monoclonal antibody for influenza. The deal provides "access to antibody and vaccine know-how and technology, and expands our ability to offer preventive health care solutions for unmet medical needs," a J&J official said.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Attorney
Blue Cross Blue Shield of Louisiana
Baton Rouge, LA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI
Senior Vice-President Managed Care Mid-Atlantic Region
Mercy Health System
Conshohocken, PA
Associate Chief Financial Officer
Commonwealth Care Alliance
Boston, MA